Press releases old

Latest press release

SUNSHINE BIOPHARMA ENTERS INTO A COLLABORATION AGREEMENT WITH A LEADING LIPID NANOPARTICLE FORMULATION COMPANY FOR ITS K1.1 ANTICANCER mRNA PROJECT

Nov 16, 2022

Montreal, Canada – (GLOBE NEWSWIRE) – Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas, including oncology and antivirals today announced that it has entered into a collaboration agreement with one of North America’s leading lipid nanoparticle (“LNP”)companies. The purpose of the collaboration is to advance the...

SUNSHINE BIOPHARMA ENTERS INTO A COLLABORATION AGREEMENT WITH A LEADING LIPID NANOPARTICLE FORMULATION COMPANY FOR ITS K1.1 ANTICANCER mRNA PROJECT

Nov 16, 2022

SUNSHINE BIOPHARMA ANNOUNCES THE ACQUISITION OF NORA PHARMA, ADDING $10.7 MILLION IN REVENUE

Oct 20, 2022

SUNSHINE BIOPHARMA FILES ITS SECOND QUARTER REPORT WITH THE SEC

Aug 4, 2022

SUNSHINE BIOPHARMA INCREASES SUPPORT FOR ANTI-CORONAVIRUS COLLABORATIVE RESEARCH WITH THE UNIVERSITY OF ARIZONA

Jul 28, 2022

Sunshine Biopharma, Inc. Announces Closing of $19.5 Million Private Placement Priced At-the-Market

Apr 28, 2022

Sunshine Biopharma, Inc. Announces Pricing of $19.5 Million Private Placement Priced At-the-Market

Apr 26, 2022

Sunshine Biopharma Files Patent Application Covering Recently Announced mRNA Molecules Found To Be Effective At Destroying Multidrug Resistant Cancer Cells

Apr 25, 2022

Sunshine Biopharma’s Newly Designed mRNA Molecules Prove Effective Against Multidrug Resistant Cancer Cells

Apr 5, 2022

Sunshine Biopharma, Inc. Announces Closing of $8.0 Million Private Placement Priced At-the-Market

Mar 14, 2022

Sunshine Biopharma Inc. Announces Pricing of $8.0 Million Private Placement Price At-the-Market

Mar 10, 2022

SUNSHINE BIOPHARMA EXPANDS ANTI-CORONAVIRUS DRUG DEVELOPMENT PROGRAM BY SIGNING A COLLABORATION AGREEMENT WITH THE UNIVERSITY OF ARIZONA

Feb 25, 2022

Sunshine Biopharma, Inc. Announces Closing of $8 Million Public Offering and Uplisting to the Nasdaq Capital Market

Feb 17, 2022

Sunshine Biopharma Inc. Announces Pricing of $8 Million Public Offering and Uplisting to the Nasdaq Capital Market

Feb 15, 2022

3 Reasons You Should Take Nutritional Supplements

Jan 18, 2022

What Are The 3 Types Of Basic Amino Acids?

Jan 14, 2022

Sunshine Biopharma Announces $1,361,000 in Debt Reduction

Dec 22, 2021

Why Are Nutrition Supplements Necessary?

Dec 14, 2021

Why You Should Be Taking Amino Acid Supplements

Dec 10, 2021

The Role Of Amino Acids And Protein In Building Muscle Mass

Nov 11, 2021

Are You Getting Your 9 Essential Amino Acids?

Nov 8, 2021

SUNSHINE BIOPHARMA EXPANDS BOARD OF DIRECTORS

Nov 3, 2021

Why Science-Based Nutrition Works

Oct 7, 2021

Sunshine Biopharma Files a Patent Application Covering mRNA Molecules for Treatment of Neurodegenerative Diseases

Oct 6, 2021

What Are Bio Pharmaceuticals And Why Do Our Bodies Need Them?

Oct 4, 2021

SUNSHINE BIOPHARMA’S CORONAVIRUS TREATMENT ANTICIPATED TO BE EFFECTIVE AGAINST DELTA AND THE OTHER VARIANTS OF CONCERN

Aug 12, 2021

Sunshine Biopharma Opens Twitter Account For Increased Shareholder Engagement

Jul 27, 2021

SUNSHINE BIOPHARMA RECEIVES $0.9 MILLION IN ADDITIONAL FUNDING FROM RB CAPITAL

Jul 20, 2021

Sunshine Biopharma Employs mRNA Vaccine Technology to Expand Its Fight Against Multidrug Resistant Cancer

Jul 8, 2021

SUNSHINE BIOPHARMA MICE STUDY FOR COVID-19 TREATMENT PROGRESSING AS PLANNED

Jun 9, 2021

SUNSHINE BIOPHARMA’S Adva-27a DESTROYS CANCER CELLS EXPRESSING P-GLYCOPROTEIN, A MARKER PRESENT IN OVER 50% OF ALL CANCER TYPES

May 25, 2021

SUNSHINE BIOPHARMA ELIMINATES $250,000 IN VARIABLE RATE CONVERTIBLE DEBT AND PROVIDES AN UPDATE ON STATUS OF OTCQB UPLISTING

May 20, 2021

SUNSHINE BIOPHARMA REPORTS IMPROVED CASH POSITION IN 2021Q1 FILING

May 13, 2021

SUNSHINE BIOPHARMA UPGRADES COVID-19 PROVISIONAL PATENT APPLICATION TO FULL PCT APPLICATION

May 4, 2021

RB CAPITAL INCREASES INVESTMENT IN SUNSHINE BIOPHARMA

Apr 22, 2021

SUNSHINE BIOPHARMA REPORTS FAVORABLE MTD RESULTS FOR COVID-19 TREATMENT

Apr 19, 2021

SUNSHINE BIOPHARMA REACHES $2,000,000+ FINANCING FOR CORONAVIRUS TREATMENT

Mar 23, 2021

SUNSHINE BIOPHARMA RECEIVES NOTICE OF ALLOWANCE FOR A NEW PATENT APPLICATION EXTENDING PROTECTION OF Adva-27a IN EUROPE UNTIL 2033

Mar 11, 2021

SUNSHINE BIOPHARMA RECEIVES RECENTLY ORDERED NEW BATCH OF Adva-27a AND INITIATES QA/QC TESTING

Mar 4, 2021

SUNSHINE BIOPHARMA LAUNCHES eCOMMERCE STORE FOR ITS SCIENCE-BASED NUTRITIONAL SUPPLEMENTS

Mar 1, 2021

Sunshine Biopharma Discusses The Progress of Its COVID-19 and Anticancer Compounds with The Stock Day Podcast

Feb 17, 2021

SUNSHINE BIOPHARMA INITIATES COVID-19 TREATMENT MICE STUDY

Feb 10, 2021

SUNSHINE BIOPHARMA SIGNS EXCLUSIVE LICENSE AGREEMENT WITH UNIVERSITY OF GEORGIA FOR COVID-19 COMPOUNDS

Feb 4, 2021

SUNSHINE BIOPHARMA RECEIVES NOTICE OF ALLOWANCE FOR A NEW PATENT APPLICATION EXTENDING PROTECTION OF Adva-27a IN CANADA UNTIL 2033

Feb 2, 2021

SUNSHINE BIOPHARMA COMPLETES APPLICATION TO UPLIST TO OTCQB

Jan 27, 2021

SUNSHINE BIOPHARMA RECEIVES FOURTH TRANCHE FROM PREVIOUSLY ANNOUNCED $2,000,000 + FINANCING FOR CORONAVIRUS TREATMENT

Jan 14, 2021

SUNSHINE BIOPHARMA’S CORONAVIRUS TREATMENT ANTICIPATED TO BE EFFECTIVE AGAINST THE NEW VARIANT IDENTIFIED IN THE UK

Dec 22, 2020

SUNSHINE BIOPHARMA ORDERS A NEW BATCH OF Adva-27a FOR TESTING ON TOPII AMPLIFIED CANCERS

Dec 8, 2020

SUNSHINE BIOPHARMA PAYS OFF CONVERTIBLE NOTES IN CASH PREVENTING NEW SHARES FROM HITTING THE MARKET

Dec 3, 2020

SUNSHINE BIOPHARMA RECEIVES THIRD TRANCHE FROM PREVIOUSLY ANNOUNCED $2,000,000 + FINANCING FOR CORONAVIRUS TREATMENT

Dec 1, 2020

SUNSHINE BIOPHARMA BELIEVES THAT AN EFFECTIVE CORONAVIRUS TREATMENT CONTINUES TO BE NECESSARY

Nov 24, 2020

Sunshine Biopharma Signs an Agreement with a Montreal-based Company to Advance the Development of Adva-27a Anticancer Compound

Nov 19, 2020

Sunshine Biopharma Signs an Agreement for Distribution of Essential-9TM in Asia and the Far East

Nov 10, 2020

SUNSHINE BIOPHARMA RECEIVES SECOND TRANCHE FROM PREVIOUSLY ANNOUNCED $2,000,000 + FINANCING FOR CORONAVIRUS TREATMENT

Oct 26, 2020

CEO of Sunshine Biopharma, Dr. Steve Slilaty, is Featured on The Stock Day Podcast

Oct 22, 2020

SUNSHINE BIOPHARMA AND UNIVERSITY OF GEORGIA TEAM UP TO DEVELOP A NEW ANTI-CORONAVIRUS DRUG

Oct 19, 2020

SUNSHINE BIOPHARMA IDENTIFIES A LEAD ANTI-CORONAVIRUS COMPOUND

Oct 7, 2020

SUNSHINE BIOPHARMA SECURES $2,000,000 FINANCING FOR CORONAVIRUS TREATMENT

Sep 15, 2020

SUNSHINE BIOPHARMA COMPLETES THE SYNTHESIS OF FOUR POTENTIAL INHIBITORS OF CORONAVIRUS PROTEASE

Aug 25, 2020

SUNSHINE BIOPHARMA FILES A PATENT APPLICATION FOR A NEW CORONAVIRUS COVID-19 TREATMENT

Jun 1, 2020

Sunshine Biopharma Receives Health Canada Approval for Essential Calcium-Vitamin DTM Supplement

Nov 6, 2019

SUNSHINE BIOPHARMA INITIATES Adva-27a XENOGRAFT STUDIES IN MICE CARRYING DIFFERENT TYPES OF HUMAN CANCER

Oct 17, 2019

Sunshine Biopharma Receives Vegan Certification for Essential 9 Amino Acids Supplement

Sep 3, 2019

In Addition to Essential 9TM, Sunshine Biopharma Launches 7 New Dietary Supplements Now Available on Amazon.ca

May 28, 2019

Sunshine Biopharma Announces that Essential 9 is Now Available in the United States on Amazon.com

May 16, 2019

SUNSHINE BIOPHARMA ANNOUNCES THAT ESSENTIAL IS NOW AVAILABLE ON AMAZON.CA

Mar 12, 2019

SUNSHINE BIOPHARMA RECEIVES NOTICE OF ALLOWANCE FOR A NEW PATENT APPLICATION EXTENDING PROTECTION OF Adva-27a ANTICANCER DRUG UNTIL 2033

Feb 4, 2019

Sunshine Biopharma Receives Health Canada Approval for Essential 9, The Company’s First Over The Counter Essential Micronutrient

Dec 17, 2018

SUNSHINE BIOPHARMA SIGNS AN AGREEMENT WITH CROCUS LABORATORIES FOR MANUFACTURING OF Adva-27a ANTICANCER DRUG

Dec 12, 2018

Read more